New drugs that inhibit blood clotting (NACOS) also called direct action anticoagulants (DAC) have shown in several clinical trials to be effective in preventing embolic events and stroke in patients with non-valvular atrial fibrillation. Some of them such as dabigatran has been used since five years  in our country. Therefore can not be considered “new” anticoagulants, currently they are called ” Direct Action Anticoagulants” (DAC), given that acts directly on key points the coagulation cascade.

We explain in different sections and slides features of these NAC/DAC (dabigatran, rivaroxaban, apixaban).